#veritac - Twitter Hashtag

about 1 year ago

🚨Missed @ASCO 🤔, we got you covered!! #ASCO2025 recap series: Breast Cancer ⬇️ 1️⃣ #DESTINYBreast09 2️⃣ #SERENA-6 3️⃣ #ASCENT-04/#KEYNOTE-D19 4️⃣ #INAVO120 5️⃣ #VERITAC-2 6️⃣ #neoCARHP 7️⃣#NeoSTAR #Medtwitter #MedX #OncTwitter #CancerResearch #Oncology #CommunityOncology #bcsm

1

12

6

3

3K

OncUpdates

@OncUpdates

about 1 year ago

Part 5: #ASCO25 recap series #VERITAC-2: Vedegestrant (first PROTAC ER degrader) 🎯Significant PFS benefit vs fulvestrant (ESR1m ER+/HER2- ABC) 5.0 vs 2.1 mo ✅ORR 18.6% vs 4% ✅Favorable safety (<5% AEs) ⏳ OS data immature #OncTwitter #Medtwitter @ErikaHamilton9 #bcsm

OncUpdates's tweet photo. Part 5: #ASCO25 recap series

#VERITAC-2: Vedegestrant (first PROTAC ER degrader)

🎯Significant PFS benefit vs fulvestrant (ESR1m ER+/HER2- ABC) 5.0 vs 2.1 mo
✅ORR 18.6% vs 4%
✅Favorable safety (<5% AEs)
⏳ OS data immature

#OncTwitter #Medtwitter @ErikaHamilton9
#bcsm https://t.co/wI4DylSgb0

0

13

4

5

1K

Geraldine Carroll @GCarroll147

over 1 year ago

Day 2: Top Takeaways from #ASCO25 on the #ASCODailyNews Podcast! -#VERITAC-2 in ER+/HER2- ESR1-mut mBC -#PANOVA-03 in LAPC GnP + TTFields -#C-POST trial in high-risk CSCC https://t.co/AHvwmf105x #OncTwitter @ASCO

0

3

0

1

252

Breast & Lung Cancer Updates @ VuMedi @Sameh_VuMedi

almost 4 years ago

Dr. Erika Hamilton @ErikaHamilton9 @SarahCannonDocs discussing Phase 2 Expansion (#VERITAC) of a Phase 1/2 Study: ARV-471, a PROTAC® ER Degrader in Advanced ER+/HER2- BC from #SABCS22 #bcsm #VuMedi #OncTwitter #ARV471 #PROTAC https://t.co/YHlelmaiPu

0

4

0

1

405

Jason A. Mouabbi MD

@JAMouabbi

almost 4 years ago · San Antonio

#VERITAC ARV-471 #PROTAC (degrade WT & Mut ER) 100% prior CDK 80% prior FUL 50% prior CTX AEs profile acceptable CBR 38% in ITT & 50% in #ESR1m 👉🏻My take I do not like CBR as a primary endpoint in P2 trials #SABCS22 @OncoAlert

1

7

1

0

EORTC Breast Cancer Group @EORTC_BCG

almost 4 years ago

@anne_schott presents the Ph2 expansion study #VERITAC: ARV-471 (ER degrader) in pretreated ER+/HER2+ ABC: CBR 37% overall, and 47% in ESR1mut; mPFS 3.7 mos overall, 5.7 in ESR1mut; Ph3 trial (ARV-471 vs. Fulvestrant) ongoing @OncoAlert @SABCSSanAntonio

EORTC_BCG's tweet photo. @anne_schott presents the Ph2 expansion study #VERITAC: ARV-471 (ER degrader) in pretreated ER+/HER2+ ABC:
CBR 37% overall, and 47% in ESR1mut;
mPFS 3.7 mos overall, 5.7 in ESR1mut;
Ph3 trial (ARV-471 vs. Fulvestrant) ongoing
@OncoAlert @SABCSSanAntonio https://t.co/O10F5mq3x2

0

5

3

1

0

Paolo Tarantino

@PTarantinoMD

almost 4 years ago

Press release by ARVINAS, unveiling the key results from the phase 2 #VERITAC trial: among patients with fairly pretreated HR+ MBC, ARV-471 achieved a CBR of 38% and mPFS of 3.7 months (5.7 months in the presence of ESR1 mutations). https://t.co/TDG8wi8pU2

PTarantinoMD's tweet photo. Press release by ARVINAS, unveiling the key results from the phase 2 #VERITAC trial: among patients with fairly pretreated HR+ MBC, ARV-471 achieved a CBR of 38% and mPFS of 3.7 months (5.7 months in the presence of ESR1 mutations).
https://t.co/TDG8wi8pU2 https://t.co/OBdzGJGKiy

4

43

12

9

0

Top Tweets for #veritac

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users